Format
Sort by
Items per page

Send to

Choose Destination

See also: TP53 tumor protein p53 in the Gene database

tp53 in Homo sapiensRattus norvegicusDanio rerioAll 169 Gene records

Search results

Items: 1 to 20 of 16170

1.

Progression Potential of Ductal Carcinoma in situ Assessed by Genomic Copy Number Profiling.

Kitamura M, Nakayama T, Mukaisho KI, Mori T, Umeda T, Moritani S, Kushima R, Tani M, Sugihara H.

Pathobiology. 2018 Oct 17:1-10. doi: 10.1159/000492833. [Epub ahead of print]

PMID:
30332671
2.

Molecular Genetics of Endometrial Carcinoma.

Bell DW, Ellenson LH.

Annu Rev Pathol. 2018 Oct 17. doi: 10.1146/annurev-pathol-020117-043609. [Epub ahead of print]

PMID:
30332563
3.

Characterizing the three-dimensional organization of telomeres in papillary thyroid carcinoma cells.

Caria P, Dettori T, Frau DV, Lichtenzstejn D, Pani F, Vanni R, Mai S.

J Cell Physiol. 2018 Oct 17. doi: 10.1002/jcp.27321. [Epub ahead of print]

PMID:
30328617
4.

Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.

Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, Veloso A, Labrot E, Wang S, Odetunde A, Ademola A, Okedere B, Mahan S, Leary R, Macomber M, Ajani M, Johnson RS, Fitzgerald D, Grundstad AJ, Tuteja JH, Khramtsova G, Zhang J, Sveen E, Hwang B, Clayton W, Nkwodimmah C, Famooto B, Obasi E, Aderoju V, Oludara M, Omodele F, Akinyele O, Adeoye A, Ogundiran T, Babalola C, MacIsaac K, Popoola A, Morrissey MP, Chen LS, Wang J, Olopade CO, Falusi AG, Winckler W, Haase K, Van Loo P, Obafunwa J, Papoutsakis D, Ojengbede O, Weber B, Ibrahim N, White KP, Huo D, Olopade OI, Barretina J.

Nat Commun. 2018 Oct 16;9(1):4181. doi: 10.1038/s41467-018-06616-0.

PMID:
30327465
5.

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.

PMID:
30327374
6.

Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/ 2- carriers.

Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Radestad AF.

Acta Obstet Gynecol Scand. 2018 Oct 16. doi: 10.1111/aogs.13485. [Epub ahead of print]

PMID:
30325501
7.

Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.

Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X.

Am J Cancer Res. 2018 Sep 1;8(9):1873-1886. eCollection 2018.

PMID:
30323979
8.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman DI, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti HS, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Salle F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Research Network T, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson G, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Oct 15. pii: CD-18-0804. doi: 10.1158/2159-8290.CD-18-0804. [Epub ahead of print]

PMID:
30322867
9.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR.

Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814. [Epub ahead of print]

PMID:
30322319
10.

Relationship between the Regulation of Caspase-8-Mediated Apoptosis and Radioresistance in Human THP-1-Derived Macrophages.

Yoshino H, Konno H, Ogura K, Sato Y, Kashiwakura I.

Int J Mol Sci. 2018 Oct 13;19(10). pii: E3154. doi: 10.3390/ijms19103154.

11.

Altered Levels of Long NcRNAs Meg3 and Neat1 in Cell and Animal models of Huntington's Disease.

Chanda K, Das S, Chakraborty J, Bucha S, Maitra A, Chatterjee R, Mukhopadhyay D, Bhattacharyya NP.

RNA Biol. 2018 Oct 15. doi: 10.1080/15476286.2018.1534524. [Epub ahead of print]

PMID:
30321100
12.

Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways.

Lupicki K, Elifio-Esposito S, Fonseca AS, Weber SH, Sugita B, Langa BC, Pereira SRF, Govender D, Panieri E, Hiss DC, Abdul-Rasool S, Cavalli LR.

Int J Oncol. 2018 Oct 10. doi: 10.3892/ijo.2018.4589. [Epub ahead of print]

PMID:
30320392
13.

Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.

Li J, Liu X, Qiao Y, Qi R, Liu S, Guo J, Gui Y, Li J, Yu H.

Front Oncol. 2018 Sep 26;8:413. doi: 10.3389/fonc.2018.00413. eCollection 2018.

14.

Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O2-· production in cancer cells.

Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal-Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, Scupoli MT, Donadelli M.

Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0288-2. [Epub ahead of print]

PMID:
30318520
15.

Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout.

Knopp Y, Geis FK, Heckl D, Horn S, Neumann T, Kuehle J, Meyer J, Fehse B, Baum C, Morgan M, Meyer J, Schambach A, Galla M.

Mol Ther Nucleic Acids. 2018 Sep 13;13:256-274. doi: 10.1016/j.omtn.2018.09.006. [Epub ahead of print]

16.

Genomic Characterization of TP53-Wild-Type Esophageal Carcinoma.

Quaas A, Heydt C, Gebauer F, Alakus H, Loeser H, Buettner R, Hillmer A, Bruns C, Merkelbach-Bruse S, Zander T, Frommolt P.

Transl Oncol. 2018 Oct 11;12(1):154-161. doi: 10.1016/j.tranon.2018.09.007. [Epub ahead of print] No abstract available.

17.

Compositional properties and codon usage of TP73 gene family.

Barbhuiya PA, Uddin A, Chakraborty S.

Gene. 2018 Oct 11. pii: S0378-1119(18)31064-3. doi: 10.1016/j.gene.2018.10.030. [Epub ahead of print]

PMID:
30316927
18.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2018 Sep 21. pii: S1533-0028(18)30390-6. doi: 10.1016/j.clcc.2018.09.005. [Epub ahead of print]

PMID:
30316684
19.

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.

Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M.

J Transl Med. 2018 Oct 13;16(1):282. doi: 10.1186/s12967-018-1650-0.

20.

Unscheduled HDAC4 repressive activity in human fibroblasts triggers TP53-dependent senescence and favours cell transformation.

Paluvai H, Di Giorgio E, Brancolini C.

Mol Oncol. 2018 Oct 13. doi: 10.1002/1878-0261.12392. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center